.Pharmacolibrary.Drugs.C_CardiovascularSystem.C01B_AntiarrhythmicsClassIAndIii.C01BC08_Encainide.Encainide

Information

Encainide is a class Ic antiarrhythmic agent previously used to treat ventricular arrhythmias, such as ventricular tachycardia. Due to concerns regarding proarrhythmic effects and increased mortality in certain patient populations, it has been withdrawn from the market in many countries and is generally not approved for current clinical use.

Pharmacokinetics

Pharmacokinetic parameters are reported for adult patients with normal renal and hepatic function following oral administration.

References

1. McAllister, CB, et al., & Wilkinson, GR (1986). Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. Xenobiotica; the fate of foreign compounds in biological systems 16(5) 483–490. DOI:10.3109/00498258609050253 PUBMED:https://pubmed.ncbi.nlm.nih.gov/3090789

2. Woosley, RL, et al., & Wilkinson, GR (1986). Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clinical pharmacology and therapeutics 39(3) 282–287. DOI:10.1038/clpt.1986.40 PUBMED:https://pubmed.ncbi.nlm.nih.gov/3081292

3. Boriani, G, et al., & Magnani, B (1990). [Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone]. Cardiologia (Rome, Italy) 35(2) 163–169. PUBMED:https://pubmed.ncbi.nlm.nih.gov/2208201

Revisions

• 06/2025 initial generated model